Canrec Plus Tablet 16mg/12.5mg 1×14’s

Canrec Plus Tablet 16mg/12.5mg 1×14’s As with other angiotensin II receptor antagonists, candesartan is indicated for the treatment  has an additive hypertensive effect when combined with a diuretic, such as chlortalidone. It is available in a combination formulation with a low dose of the thiazide diuretic hydrochlorothiazide. Candesartan/hydrochlorothiazide combination preparations are marketed under various trade names including Atacand HCT, Hytacand, Blopress Plus, Advantec and Ratacand Plus.

In a four-year randomized controlled trial, candesartan was compared to placebo to see whether it could prevent or postpone the development of full-blown hypertension in people with so-called prehypertension. During the first two years of the trial, half of participants were given candesartan, and the others received placebo; candesartan reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan had significantly reduced the risk of hypertension, by more than 15%. Serious adverse effects were more common among participants receiving placebo than in those given candesartan.

As with other drugs that inhibit the renin–angiotensin system, if candesartan is taken by pregnant women during the second or third trimester, it can cause injury and in some cases, death of the developing fetus.

A meta-analysis found that candesartan reduces risk of atrial fibrillation in persons with systolic left ventricular dysfunction or with left ventricular hypertrophy.(This was also true of other angiotensin receptor blockers converting enzyme inhibitors).